Stock COV COVALON TECHNOLOGIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Covalon Technologies Ltd.

Equities

COV

CA22282D3022

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 16:04:32 09/05/2024 BST 		5-day change 1st Jan Change
1.09 CAD +2.83% Intraday chart for Covalon Technologies Ltd. +7.92% +2.83%
03-06 Transcript : Covalon Technologies Ltd. - Shareholder/Analyst Call
02-28 Covalon Technologies Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Capitalization 1 186.6 59.38 30.98 65.45 61.34 37
Enterprise Value (EV) 1 182.6 67.9 48.38 42.54 48.08 29.77
P/E ratio 121 x -5.61 x -4.44 x 2.78 x -6.44 x -8.33 x
Yield - - - - - -
Capitalization / Revenue 6.98 x 1.75 x 1.2 x 3.35 x 3.38 x 1.39 x
EV / Revenue 6.83 x 2 x 1.88 x 2.17 x 2.65 x 1.12 x
EV / EBITDA 97.9 x -9.35 x -9.56 x 85.8 x -5.68 x -7.53 x
EV / FCF -90 x -15.8 x -19 x -441 x -8.01 x -11 x
FCF Yield -1.11% -6.33% -5.26% -0.23% -12.5% -9.08%
Price to Book 14.3 x 3.98 x 3.4 x 1.96 x 2.53 x 1.97 x
Nbr of stocks (in thousands) 21,952 25,819 25,819 25,869 25,347 24,670
Reference price 2 8.500 2.300 1.200 2.530 2.420 1.500
Announcement Date 17/12/18 28/01/20 28/01/21 13/12/21 25/01/23 26/01/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net sales 1 26.72 34 25.8 19.56 18.15 26.6
EBITDA 1 1.866 -7.263 -5.06 0.4958 -8.461 -3.954
EBIT 1 1.618 -7.776 -5.619 0.0365 -9.142 -4.528
Operating Margin 6.05% -22.87% -21.78% 0.19% -50.38% -17.03%
Earnings before Tax (EBT) 1 1.618 -9.138 -6.952 0.419 -9.254 -4.461
Net income 1 1.618 -9.138 -6.952 23.48 -9.663 -4.461
Net margin 6.05% -26.87% -26.95% 120.02% -53.25% -16.77%
EPS 2 0.0700 -0.4100 -0.2700 0.9092 -0.3759 -0.1800
Free Cash Flow 1 -2.03 -4.3 -2.547 -0.0965 -5.999 -2.703
FCF margin -7.59% -12.65% -9.87% -0.49% -33.06% -10.16%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 17/12/18 28/01/20 28/01/21 13/12/21 25/01/23 26/01/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net Debt 1 - 8.52 17.4 - - -
Net Cash position 1 3.96 - - 22.9 13.3 7.23
Leverage (Debt/EBITDA) - -1.173 x -3.438 x - - -
Free Cash Flow 1 -2.03 -4.3 -2.55 -0.1 -6 -2.7
ROE (net income / shareholders' equity) 14.6% -65.1% -57.8% 1.97% -32.1% -20.7%
ROA (Net income/ Total Assets) 6.38% -16.4% -9.45% 0.06% -16.1% -10.2%
Assets 1 25.34 55.76 73.55 38,741 60 43.56
Book Value Per Share 2 0.6000 0.5800 0.3500 1.290 0.9600 0.7600
Cash Flow per Share 2 0.2500 0.3700 0.1400 0.9900 0.6100 0.3600
Capex 1 0.73 1.26 0.37 0.18 0.6 0.49
Capex / Sales 2.72% 3.72% 1.44% 0.9% 3.31% 1.86%
Announcement Date 17/12/18 28/01/20 28/01/21 13/12/21 25/01/23 26/01/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
COVALON TECHNOLOGIES LTD. Stock Covalon Technologies Ltd.
+2.83% 19.68M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. COV Stock
  4. Financials Covalon Technologies Ltd.